ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/β-catenin activity

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 404-411

  Zhang, Kailiang ^a,b   Zhu, Shanjun ^a,b   Liu, Yanwei ^b,c   Dong, Xiaoqun ^d   Shi, Zhendong ^a,b   Zhang, Anling ^a,b   Liu, Chaoyong ^e   Chen, Luyue ^a,b   Wei, Jianwei ^a,b   Pu, Peiyu ^a,b   Zhang, Jianning ^a,b   Jiang, Tao ^b,d   Han, Lei ^a,b   Kang, Chunsheng ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Chinese Glioma Cooperative Group (CGCG)   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e TIANJIN UNIVERSITY   (China)

Author keywords

Glioma; ICAT; Proliferation; Wnt; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; INHIBITOR OF BETA CATENIN AND T CELL FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; CTNNBIP1 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DOWN REGULATION; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOCITRATE DEHYDROGENASE; MICE; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TRANSFECTION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920454116     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.047     Document Type: Article

References (28)

1. Gonzalez-Sancho J.M., Aguilera O., Garcia J.M., Pendas-Franco N., Pena C., Cal S., et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 2005, 24:1098-1103.
2. Yook J.I., Li X.Y., Ota I., Hu C., Kim H.S., Kim N.H., et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol 2006, 8:1398-1406.
3. Verras M., Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 2006, 237:22-32.
4. Pu P., Zhang Z., Kang C., Jiang R., Jia Z., Wang G., et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009, 16:351-361.
5. Zhang K., Zhang J., Han L., Pu P., Kang C. Wnt/beta-catenin signaling in glioma. J. Neuroimmune Pharmacol 2012, 7:740-749.
6. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 2005, 8:727-738.
7. Zhang K.L., Han L., Chen L.Y., Shi Z.D., Yang M., Ren Y., et al. Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. Cancer Lett 2014, 342:139-149.
8. Zhang K.L., Zhou X., Han L., Chen L.Y., Chen L.C., Shi Z.D., et al. MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Mol. Cancer 2014, 13:63.
9. Chen L., Han L., Zhang K., Shi Z., Zhang J., Zhang A., et al. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro-Oncol 2012, 14:1026-1036.
10. Tago K., Nakamura T., Nishita M., Hyodo J., Nagai S., Murata Y., et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 2000, 14:1741-1749.
11. Reifenberger J., Knobbe C.B., Wolter M., Blaschke B., Schulte K.W., Pietsch T., et al. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 2002, 100:549-556.
12. Sekiya T., Nakamura T., Kazuki Y., Oshimura M., Kohu K., Tago K., et al. Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin. Cancer Res 2002, 62:3322-3326.
13. Han L., Zhang K.L., Zhang J.X., Zeng L., Di C.H., Fee B.E., et al. AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization. CNS Neurosci. Ther 2014, 20:429-437.
14. Shi Z., Zhang J., Qian X., Han L., Zhang K., Chen L., et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res 2013, 73:5519-5531.
15. Domingues M.J., Rambow F., Job B., Papon L., Liu W., Larue L., et al. β-catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer Res 2014, 74:1983-1995.
16. Koyama T., Tago K., Nakamura T., Ohwada S., Morishita Y., Yokota J., et al. Mutation and expression of the beta-catenin-interacting protein ICAT in human colorectal tumors. Jpn. J. Clin. Oncol 2002, 32:358-362.
17. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med 2009, 360:765-773.
18. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
19. Lin P.L., Wu D.W., Huang C.C., He T.Y., Chou M.C., Sheu G.T., et al. MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of beta-catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer. Carcinogenesis 2014, 35:2175-2182.
20. Brabletz T., Jung A., Hermann K., Gunther K., Hohenberger W., Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract 1998, 194:701-704.
21. Shi Z., Qian X., Li L., Zhang J., Zhu S., Zhu J., et al. Nuclear translocation of beta-catenin is essential for glioma cell survival. J. Neuroimmune Pharmacol 2012, 7:892-903.
22. Liu X., Wang L., Zhao S., Ji X., Luo Y., Ling F. β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Med. Oncol 2011, 28:608-614.
23. Wang K., Wang X., Zou J., Zhang A., Wan Y., Pu P., et al. miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro-Oncol 2013, 15:578-588.
24. Dihlmann S., Siermann A., von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 2001, 20:645-653.
25. Bauer K., Dowejko A., Bosserhoff A.K., Reichert T.E., Bauer R. Slit-2 facilitates interaction of P-cadherin with Robo-3 and inhibits cell migration in an oral squamous cell carcinoma cell line. Carcinogenesis 2011, 32:935-943.
26. Ma H., Nguyen C., Lee K.S., Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005, 24:3619-3631.
27. Pannequin J., Delaunay N., Buchert M., Surrel F., Bourgaux J.F., Ryan J., et al. Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors. Gastroenterology 2007, 133:1554-1568.
28. Houillier C., Wang X., Kaloshi G., Mokhtari K., Guillevin R., Laffaire J., et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010, 75:1560-1566.